Dear subscribers, we haven’t issued an alert in awhile and we do appologize. It has been long overdue and now we believe we found a newer trading stock that could possibly explode. If you’re no longer insterested in our newsletter, we understand, please click the link at the bottom of the email to be removed.
Here is our NEW subscriber only Watch Alert: OncoSec Medical Inc. (ONCS.OB)
OnSec Medical Inc., an advanced-stage biomedical oncology company, has been trading only for a few weeks and already has a target issued on it–which it’s starting to close in on quickly. On May 26th Vista Partners, an equity research firm, sent out a press release issuing a full report along with their target for ONCS. An excerpt of the report is below.
Snippet of Vista’s report below. Click to download the full 21 page report.
Here is another excerpt within the report–Look at the highlighted results: OncoSec Medical Inc. has already completed Phase I trials, using electroporation to deliver plasmid-DNA encoding for the cytokine, IL-12. The study was designed to assess both the adaptive and innate immunity responses from the targeted delivery of the IL-12 into melanoma tumor cells. Published data have demonstrated that gene transfer utilizing in vivo DNA electroporation in metastatic melanoma showed that it was safe, effective, reproducible, and titratable. 90% of locally treated melanoma skin lesions achieved complete or partial regression. The findings also demonstrated 100% clearance of distant untreated lesions in 15% of the patients, suggesting a systemic immune response resulting from the localized treatment. In contrast, only 0.25% of melanoma skin lesions would be expected to spontaneously regress if left untreated. These results are of great significance and thus the Company is now planning a Phase II clinical trial to assess IL-12 plasmid-DNA delivered using the OMS electroporation delivery system. This trial is expected to begin before the end of 2011.
ONCS has already a solid trading base with great avg. volume and is currently smashing any resistance on its way to the top of the charts. This can be great for fast pop’s into the green.
Check out the chart below.
OncoSec Medical Chart
Set your trade trigger for ONCS now! Keep a close eye out Tuesday morning for a potential run and BOOK ANY GAINS EARLY.
See you in the green!
-OTC Stocks Watch Trading Staff
Otcstockswatch.com has NOT been compensated for this information you are receiving. Otcstockswatch.com is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission’s penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.
Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission (“SEC”) filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review atRecipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website at Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as “believes”, “expects”, “may”, “will”, or “should”, or “anticipates”. Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company’s operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.
Fully read our before making any investment decisions
